[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642746":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":40,"centralContacts":45,"locations":54,"responsibleParty":308,"collaborators":31,"id":310,"slug":31,"hasResults":311,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":31,"eligibilityCriteria":315,"healthyVolunteers":311,"sex":316,"minAge":317,"maxAge":318,"enrollmentInfo":319,"targetDuration":31,"studyType":322,"phases":323,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":330,"whyStopped":31,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":340},{"fullName":5,"class":6},"Chinese SLE Treatment And Research Group","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Tocilizumab group","EXPERIMENTAL","Tocilizumab will be administered intravenously at a dose of 8 mg\u002Fkg every 4 weeks for 52 weeks in combination with csDMARD.",[13],"Drug: Tocilizumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Telitacicept group","Telitacicept will be administered by subcutaneous injection at a dose of 160 mg once weekly for 52 weeks in combination with csDMARD.",[18],"Drug: Telitacicept",{"label":20,"type":21,"description":22,"interventionNames":23},"Methotrexate group","ACTIVE_COMPARATOR","Methotrexate will be administered orally at a dose of 15 mg once weekly for 52 weeks in combination with stable background immunosuppressive therapy.",[24],"Drug: Methotrexate",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Tocilizumab","Tocilizumab will be administered intravenously at a dose of 8 mg\u002Fkg every 4 weeks in addition to stable background csDMARD therapy maintained throughout the study period.",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Telitacicept","Telitacicept will be administered by subcutaneous injection at a dose of 160 mg once weekly in addition to stable background csDMARD therapy maintained throughout the study period",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Methotrexate","Methotrexate will be administered orally at a dose of 15 mg once weekly in addition to stable background csDMARD therapy",[20],[41],{"name":42,"affiliation":43,"role":44},"Xinping Tian","Peking Union Medical College Hospital","PRINCIPAL_INVESTIGATOR",[46,50],{"name":42,"role":47,"phone":48,"phoneExt":31,"email":49},"CONTACT","+86-13691165939","tianxp6@126.com",{"name":51,"role":47,"phone":52,"phoneExt":31,"email":53},"Shangyi Jin","+86-1367049688","jinjinboli@sina.com",[55,70,82,91,99,108,116,128,140,152,164,176,188,200,212,224,236,248,260,272,284,296],{"facility":56,"status":31,"city":57,"state":58,"zip":31,"country":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"The First Affiliated Hospital of Henan University of Science and Technology","Luoyang","Henan","China",{"type":61,"coordinates":62},"Point",[63,64],112.43684,34.67345,{"lat":64,"lon":63},[67,69],{"name":68,"role":47,"phone":31,"phoneExt":31,"email":31},"Xiaofei Shi",{"name":68,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":71,"status":31,"city":72,"state":31,"zip":31,"country":59,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Beijing Chao-Yang Hospital, Capital Medical University","Beijing",{"type":61,"coordinates":74},[75,76],116.39723,39.9075,{"lat":76,"lon":75},[79,81],{"name":80,"role":47,"phone":31,"phoneExt":31,"email":31},"Juan Meng",{"name":80,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":83,"status":31,"city":72,"state":31,"zip":31,"country":59,"cosmosGeoPoint":84,"geoPoint":86,"contacts":87},"China-Japan Friendship Hospital",{"type":61,"coordinates":85},[75,76],{"lat":76,"lon":75},[88,90],{"name":89,"role":47,"phone":31,"phoneExt":31,"email":31},"Xin Lu",{"name":89,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":43,"status":31,"city":72,"state":31,"zip":31,"country":59,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},{"type":61,"coordinates":93},[75,76],{"lat":76,"lon":75},[96,98],{"name":51,"role":47,"phone":97,"phoneExt":31,"email":53},"+86-13671049688",{"name":42,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":100,"status":31,"city":72,"state":31,"zip":31,"country":59,"cosmosGeoPoint":101,"geoPoint":103,"contacts":104},"Xuanwu Hospital, Capital Medical University",{"type":61,"coordinates":102},[75,76],{"lat":76,"lon":75},[105,107],{"name":106,"role":47,"phone":31,"phoneExt":31,"email":31},"Yi Zhao",{"name":106,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":109,"status":31,"city":110,"state":31,"zip":31,"country":59,"cosmosGeoPoint":111,"geoPoint":115,"contacts":31},"China-Japan Union Hospital of Jilin University","Changchun",{"type":61,"coordinates":112},[113,114],125.32278,43.88,{"lat":114,"lon":113},{"facility":117,"status":31,"city":118,"state":31,"zip":31,"country":59,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"The First Affiliated Hospital of Army Medical University (Southwest Hospital)","Chongqing",{"type":61,"coordinates":120},[121,122],106.55771,29.56026,{"lat":122,"lon":121},[125,127],{"name":126,"role":47,"phone":31,"phoneExt":31,"email":31},"Qinghua Zou",{"name":126,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":129,"status":31,"city":130,"state":31,"zip":31,"country":59,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"The Second Affiliated Hospital of Dalian Medical University","Dalian",{"type":61,"coordinates":132},[133,134],121.60222,38.91222,{"lat":134,"lon":133},[137,139],{"name":138,"role":47,"phone":31,"phoneExt":31,"email":31},"Xiaodan Kong",{"name":138,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":141,"status":31,"city":142,"state":31,"zip":31,"country":59,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Handan Central Hospital","Handan",{"type":61,"coordinates":144},[145,146],114.48764,36.60999,{"lat":146,"lon":145},[149,151],{"name":150,"role":47,"phone":31,"phoneExt":31,"email":31},"Xi Liu",{"name":150,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":153,"status":31,"city":154,"state":31,"zip":31,"country":59,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"The Second Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou",{"type":61,"coordinates":156},[157,158],120.16142,30.29365,{"lat":158,"lon":157},[161,163],{"name":162,"role":47,"phone":31,"phoneExt":31,"email":31},"Jing Xue",{"name":162,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":165,"status":31,"city":166,"state":31,"zip":31,"country":59,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"The First Affiliated Hospital of Anhui Medical University","Hefei",{"type":61,"coordinates":168},[169,170],117.28083,31.86389,{"lat":170,"lon":169},[173,175],{"name":174,"role":47,"phone":31,"phoneExt":31,"email":31},"Shengqian Xu",{"name":174,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":177,"status":31,"city":178,"state":31,"zip":31,"country":59,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"Affiliated Hospital of Inner Mongolia Medical University","Hohhot",{"type":61,"coordinates":180},[181,182],111.65222,40.81056,{"lat":182,"lon":181},[185,187],{"name":186,"role":47,"phone":31,"phoneExt":31,"email":31},"Hongbin Li",{"name":186,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":189,"status":31,"city":190,"state":31,"zip":31,"country":59,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Jiujiang No. 1 People's Hospital","Jiujiang",{"type":61,"coordinates":192},[193,194],116.00206,29.70475,{"lat":194,"lon":193},[197,199],{"name":198,"role":47,"phone":31,"phoneExt":31,"email":31},"Ju Liu",{"name":198,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":201,"status":31,"city":202,"state":31,"zip":31,"country":59,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"The Second Hospital of Lanzhou University","Lanzhou",{"type":61,"coordinates":204},[205,206],103.83987,36.05701,{"lat":206,"lon":205},[209,211],{"name":210,"role":47,"phone":31,"phoneExt":31,"email":31},"Haili Shen",{"name":210,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":213,"status":31,"city":214,"state":31,"zip":31,"country":59,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"The Second Affiliated Hospital of Nanchang University","Nanchang",{"type":61,"coordinates":216},[217,218],115.85306,28.68396,{"lat":218,"lon":217},[221,223],{"name":222,"role":47,"phone":31,"phoneExt":31,"email":31},"Xinwang Duan",{"name":222,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":225,"status":31,"city":226,"state":31,"zip":31,"country":59,"cosmosGeoPoint":227,"geoPoint":231,"contacts":232},"The First Affiliated Hospital of Nanjing Medical University","Nanjing",{"type":61,"coordinates":228},[229,230],118.77778,32.06167,{"lat":230,"lon":229},[233,235],{"name":234,"role":47,"phone":31,"phoneExt":31,"email":31},"Wenfeng Tan",{"name":234,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":237,"status":31,"city":238,"state":31,"zip":31,"country":59,"cosmosGeoPoint":239,"geoPoint":243,"contacts":244},"The First Affiliated Hospital of Guangxi Medical University","Nanning",{"type":61,"coordinates":240},[241,242],108.31667,22.81667,{"lat":242,"lon":241},[245,247],{"name":246,"role":47,"phone":31,"phoneExt":31,"email":31},"Ling Lei",{"name":246,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":249,"status":31,"city":250,"state":31,"zip":31,"country":59,"cosmosGeoPoint":251,"geoPoint":255,"contacts":256},"Shanxi Bethune Hospital","Taiyuan",{"type":61,"coordinates":252},[253,254],112.56028,37.86944,{"lat":254,"lon":253},[257,259],{"name":258,"role":47,"phone":31,"phoneExt":31,"email":31},"Liyun Zhang",{"name":258,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":261,"status":31,"city":262,"state":31,"zip":31,"country":59,"cosmosGeoPoint":263,"geoPoint":267,"contacts":268},"The First Affiliated Hospital of Xinjiang Medical University","Ürümqi",{"type":61,"coordinates":264},[265,266],87.60046,43.80096,{"lat":266,"lon":265},[269,271],{"name":270,"role":47,"phone":31,"phoneExt":31,"email":31},"Li Luo",{"name":270,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":273,"status":31,"city":274,"state":31,"zip":31,"country":59,"cosmosGeoPoint":275,"geoPoint":279,"contacts":280},"Xingyi People's Hospital","Xingyi",{"type":61,"coordinates":276},[277,278],104.90639,25.09617,{"lat":278,"lon":277},[281,283],{"name":282,"role":47,"phone":31,"phoneExt":31,"email":31},"Houli Liao",{"name":282,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":285,"status":31,"city":286,"state":31,"zip":31,"country":59,"cosmosGeoPoint":287,"geoPoint":291,"contacts":292},"Affiliated Hospital of Yan'an University","Yan’an",{"type":61,"coordinates":288},[289,290],109.49167,36.59889,{"lat":290,"lon":289},[293,295],{"name":294,"role":47,"phone":31,"phoneExt":31,"email":31},"Yuhong Liu",{"name":294,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":297,"status":31,"city":298,"state":31,"zip":31,"country":59,"cosmosGeoPoint":299,"geoPoint":303,"contacts":304},"People's Hospital of Ningxia Hui Autonomous Region","Yinchuan",{"type":61,"coordinates":300},[301,302],106.27306,38.46806,{"lat":302,"lon":301},[305,307],{"name":306,"role":47,"phone":31,"phoneExt":31,"email":31},"Donggeng Guo",{"name":306,"role":44,"phone":31,"phoneExt":31,"email":31},{"type":309,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100642746",false,"NCT07643038","Treatment Strategy for Patients With RA-ILD","Treatment Strategy for Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease","Inclusion Criteria:\n\n* Fulfillment of the 2010 ACR\u002FEULAR classification criteria for RA.\n* HRCT findings consistent with interstitial lung disease (ILD), including ground-glass opacities, reticular abnormalities, fibrotic linear opacities, traction bronchiectasis, or other compatible features, with pulmonary infection, cardiogenic pulmonary edema, and alveolar hemorrhage excluded. The extent of ILD involvement must be ≥20% on HRCT, as assessed by central review.\n* Pulmonary function impairment defined as forced vital capacity (FVC) \\\u003C80% of predicted and\u002For diffusing capacity of the lung for carbon monoxide (DLCO) \\\u003C70% of predicted.\n* Participants receiving glucocorticoids prior to enrollment must be on a stable dose of prednisone ≤10 mg\u002Fday (or equivalent) for at least 4 weeks before baseline.\n* Participants receiving a csDMARD prior to enrollment must be on a stable regimen for at least 4 weeks before baseline.\n* Able and willing to provide written informed consent and comply with study requirements, including scheduled visits and follow-up assessments.\n\nExclusion Criteria:\n\n* Presence of other autoimmune diseases.\n* Presence of severe, uncontrolled clinically significant organ dysfunction or other medical conditions that, in the investigator's judgment, would place the participant at unacceptable risk.\n* History of malignancy within 5 years prior to screening.\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study period.\n* Known hypersensitivity to tocilizumab, telitacicept, methotrexate, or any of their excipients.\n* Active hepatitis B or C virus infection, active tuberculosis, active herpes zoster infection, or a history of serious infection within 12 weeks prior to study treatment initiation (defined as an infection requiring hospitalization or intravenous antimicrobial therapy).\n* Severe hypoalbuminemia or serum immunoglobulin G (IgG) level \\\u003C6 g\u002FL.\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × the upper limit of normal (ULN), total bilirubin \\>1.5 × ULN, or creatinine clearance (CrCl) \\\u003C60 mL\u002Fmin.\n* Participation in another interventional clinical trial within 4 weeks prior to screening.\n* Inability to adequately perform pulmonary function testing or other study-related assessments.\n* Any other condition that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.","ALL","18 Years","80 Years",{"count":320,"type":321},204,"ESTIMATED","INTERVENTIONAL",[324],"PHASE4","This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.",[327],"Rheumatoid Arthritis Associated Interstitial Lung Disease",[329,33,28],"randomized controlled trial","NOT_YET_RECRUITING","2026-06-07",{"date":333,"type":334},"2026-06-11","ACTUAL",{"date":336,"type":321},"2026-07-01",{"date":338,"type":321},"2029-07-31",{"name":5,"class":6},22]